Listen to Guy Sauvageau’s interview at the ESH 5th International Conference on AML
Click on Guy Sauvageau’s interview last october on why should we target RUNX1 in AML treatment.
Vincent Lavallée’s Laboratory is joining the Leucegene group!
Vincent will bring his expertise in single cell sequencing analysis! Positions are available in his laboratory which opened on October 2019 at CHU Sainte-Justine Research Center. Please visit www.lavalleelab.com for more details.
The Cost-effectiveness analysis of HMGA2 prognostic test for AML is now published
Cost-effectiveness analysis of a HMGA2 prognostic test for acute myeloid leukemia in a Canadian setting is now available in Applied Health Economics and Health Policy.
New publication in Blood
H3K27M/I mutations promote context-dependent transformation in acute myeloid leukemia with RUNX1 alterations is now published in Blood.